Home Featured Page 112

Featured

Latest

Michael Ryoshin Sapiro, PsyD – Truth Medicine, Psychedelics, and Living Your Truth

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic Work

Navigators Film Club – Last Journey

Key Psychedelic Research Themes in 2022

PT388 – Vital Psychedelic Conversations

Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent...

Bullseye Chart: The Psychedelic Drug Development Pipeline

Israeli- Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics...

Opinions | Australia’s Rescheduling of MDMA and Psilocybin a Welcome First...

Panel: Neuroimaging in Psychedelic Research

PT387 – Psychedelic Ethics & Self-Reflexivity and Proposition 122 Conflict &...

Optimi Health Submits Phase I Clinical Trial Application Combining The Use...

PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New...

1...111112113...303 Page 112 of 303

Michael Ryoshin Sapiro, PsyD – Truth Medicine, Psychedelics, and Living Your...

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Michael Ryoshin Sapiro, PsyD – Truth Medicine, Psychedelics, and Living Your Truth

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic Work

Navigators Film Club – Last Journey

Key Psychedelic Research Themes in 2022

PT388 – Vital Psychedelic Conversations

Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent...

Bullseye Chart: The Psychedelic Drug Development Pipeline

Israeli- Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics...

Opinions | Australia’s Rescheduling of MDMA and Psilocybin a Welcome First...

Panel: Neuroimaging in Psychedelic Research

PT387 – Psychedelic Ethics & Self-Reflexivity and Proposition 122 Conflict &...

Optimi Health Submits Phase I Clinical Trial Application Combining The Use...

PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New...

EDITOR PICKS

Michael Ryoshin Sapiro, PsyD – Truth Medicine, Psychedelics, and Living Your...

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY